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Nonpolymeric Hydroxyapatite Coated Coronary
tent, Reduces Signs of Delayed Healing
im J. van der Giessen, MD, PHD,*† Oana Sorop, PHD,* Patrick W. Serruys, MD, PHD,*
lona Peters-Krabbendam, BSC,* Heleen M. M. van Beusekom, PHD*
otterdam and Utrecht, the Netherlands
bjectives The aim of this study was to compare efﬁcacy of low- and high-dose sirolimus release
25, 40, or 100 g) from hydroxyapatite (HAp) with Cypher (Cordis, Johnson & Johnson, Warren,
ew Jersey) (111 g sirolimus) in porcine coronary arteries.
ackground Polymer-based sirolimus-eluting stents such as Cypher interfere with vascular healing,
robably due to the permanent presence of the polymer coating and the high sirolimus dose. The
se of low-dose sirolimus and inert nonpolymeric but biodegradable coatings such as HAp might be
ore appropriate.
ethods Stents (n  68) were implanted, guided by quantitative coronary angiography. All swine
eceived clopidogrel and acetylsalicylic acid during 28 days follow-up. Safety of the coating in ab-
ence of drugs was studied by comparing HAp with and without a lipid-based release regulating
ayer (HApR) with bare-metal stents. Efﬁcacy was studied by comparing the release of 25, 40, and
00 g sirolimus with Cypher.
esults The safety study (without drug) revealed no differences in neointimal thickening in re-
ponse to HAp and HApR with complete healing in all groups. Dose response analysis showed that
eointimal thickening was similar in all groups regardless of sirolimus dose, with a normal appear-
nce of the endothelium. There was, however, a dose-dependent increase in ﬁbrinoid (p  0.028),
onsidered to be a marker of delayed healing. The Cypher stent induced the highest amount of
brinoid.
onclusions Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent
educes signs of delayed vascular healing, without affecting neointimal hyperplasia. (J Am Coll
ardiol Intv 2009;2:284–90) © 2009 by the American College of Cardiology Foundation
rom the *Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands; and the †Interuniversity Cardiology
nstitute-KNAW, Utrecht, the Netherlands. This work was partly supported by MIV Therapeutics Inc. Bernard Meier, MD,
erved as Guest Editor for this paper.anuscript received October 2, 2008; revised manuscript received November 27, 2008, accepted December 3, 2008.
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285n important limitation of current drug-eluting stents
DES) are their association with delayed healing as well as
heir negative effect on endothelium-dependent vasomotor
unction distal to the stent, which can even extend into the
icrovasculature (1–5). Toxic tissue reactions to the poly-
er coatings and the relatively high drug levels might
xplain these processes. Although it remains to be deter-
ined whether delayed healing in DES is truly associated
ith late stent thrombosis (6,7), it is clear that higher drug
oses at overlapping stent sites do affect vascular healing (8).
ower but still effective drug doses in combination with
onpolymeric coatings might be advantageous in reducing
ll of these phenomena.
In the present study we tested the biocompatibility and
fficacy of a polymer-free base coating consisting of hydroxy-
patite (HAp) with and without a drug release regulating lipid
ayer (HApR) eluting incremental doses of sirolimus (25, 40,
nd 100 g). Outcome was compared with the commercially
vailable polymer-based DES Cypher (Cordis, Johnson &
ohnson, Warren, New Jersey). End points were neointimal
ormation, delayed healing, and vascular injury in a swine
odel of coronary stenting.
ethods
nimals. Experiments were performed in farm-bred swine
Yorkshire-Landrace, 30 to 35 kg) as previously described
9). The study complied with the regulations of the animal
are committee of the Erasmus University Rotterdam and the
Guide for the Care and Use of Laboratory Animals”
National Institutes of Health publication 85-23).
tents. All stents are based on a 316L stainless steel
low-magnetic, low-carbon) balloon-expandable coronary
tent (length 16 mm, width 3.0 and 3.5 mm) built by MIV
herapeutics, Atlanta, Georgia. As a control, Cypher stents
Cordis, Johnson & Johnson; length 13 mm, width 3.0 mm)
ere used.
oatings. The study-coatings are based on nonpolymeric
Ap (Fig. 1) with a drug release regulating lipid layer
HApR) for regulating the release of higher doses of
irolimus. In vitro testing on crimped and expanded stents at
7°C in 7.4 PH buffered saline demonstrates a drug release
ate (in g drug/time point) that is almost the same as that
eleased by Cypher during the first hour. In vitro drug
elease is calculated to reach 100% in approximately 3 to 4
eeks (data are on file at MIV Therapeutics). Coating
haracteristics are summarized in Table 1.
The Cypher stent releases sirolimus from a mixture of 2
on-erodible polymers (polyethylene-co-vinyl acetate and
oly-butyl-methacrylate) that are combined (67% and 33%,
espectively) and then applied to a parylene-C coated stent.
drug-free top-layer of poly-butyl-methacrylate serves to
revent a burst effect. The stent was designed to release 80%
f the drug within 30 days. pES study. The safety and efficacy of the polymer-free HAp
oating was assessed by comparing HAp (n 6) and HApR
n  6) with HAp releasing 25 g and HApR releasing 40
g and 100 g sirolimus (n  13/dose) with Cypher
ontaining 111 g sirolimus (n  13) at 28 days follow-up.
ll animals received 3 different stents each, 1/coronary
rtery, according to a predetermined randomization scheme.
nimal preparation. Animals were prepared as described
arlier (10). In short, animals were pretreated with 300 mg
cetylsalicylic acid (ASA) and a loading dose of 300 mg of
lopidogrel (Plavix, Sanofi Aventis, Gouda, the Nether-
ands) 1 day before the procedure. After induction of
nesthesia and connection to the ventilator, antibiotic pro-
hylaxis was administered by an intramuscular injection of
treptomycin, penicillin procaine (0.1 mg/kg). An intro-
ucer sheath was placed in the carotid artery for arterial
ccess. A dose of 250 mg ASA and 10,000 IU heparin was
dministered (i.a.).
tent implantation and angiography. Stent implantation
as performed as described earlier (9,10). Under guidance
f quantitative angiography (CAAS II, PIE Medical, Maas-
richt, the Netherlands), arterial
egments of 2.5 to 3.2 mm in
iameter were selected in each of
he coronary arteries. Stents
ere placed with a balloon/
rtery ratio of 1.1 according to a
redetermined scheme (random
lock design). After the final
uantitative angiogram, the ani-
al was allowed to recover from
nesthesia and returned to the
nimal care facilities for the
ostoperative recovery. During the follow-up period, 300
g ASA and 75 mg clopidogrel were administered daily.
ollow-up study. At 28 days follow-up, animals were anes-
hetized; quantitative angiography was repeated, followed
y killing through an overdose of pentobarbital. Hearts were
ressure fixed in situ with 500 ml 4% buffered formaldehyde
n preparation for histology and immunocytochemistry (10).
istology. The arteries, including 1 to 2 cm of coronary
essel both proximally and distally adjacent to the stent,
ere processed for plastic embedding (11,12). Sections were
ollected from the nonstented adjacent artery and at 3 levels
the proximal, medial, and distal part of the stent) from the
tented segments and stained with hematoxylin-eosin and
esorcin fuchsin (elastin stain) for quantitative and qualita-
ive analysis.
orphometry. Morphometric analysis, inflammatory score,
nd injury score analysis were performed as described earlier
13,14). Inflammatory scores were determined by the pres-
nce of inflammatory cells surrounding the stent struts, “no
nflammation” being defined as no inflammatory cells being
Abbreviations
and Acronyms
ASA  acetylsalicylic acid
DES  drug-eluting stent(s)
HAp  hydroxyapatite
HApR  hydroxyapatite
including drug release
regulating lipid layer
QCA  quantitative coronary
angiographyresent around the struts and “full inflammation” meaning
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286hat all struts proximal, mid, and distal were surrounded by
nflammatory cells.
tatistical analysis. All data are given as mean  SD and
ere analyzed with SPSS (SPSS Inc. version 11.5.0, Chi-
ago, Illinois), with the stent as the unit of analysis, not the
nimal.
Intergroup differences were initially assessed with analysis
f variance with a post hoc Bonferroni correction. Statistical
ignificance was considered for p  0.05. Linear regression
Figure 1. Scanning Electron Microscopy of the HAp Coating
Scanning electron microscopy of the hydroxyapatite (HAp) coating showing th
ness of the coating is approximately 0.6 m. The expanded HAp-coated stentnalysis was performed to take into account the effect of ao-factors on outcome. These factors, to include the whole
rocedure, were: 1) stent characteristics (presence of HAp,
elease layer, and drug dose); 2) procedural characteristics
coronary diameter before stenting, stent/artery ratio, acute
ain); and 3) histological characteristics (intimal inflamma-
ion, morphologic injury score). Dummy variables were
ncluded to assess differences between the study-groups.
ogistic regression was performed with sirolimus dose as a
ariable to predict fibrinoid (best 2 tertiles vs. worst) for
h surface (A) that is considerably smoothed by drug-loading (B). The thick-
ows some roughening at areas of higher stress.e rougssessment of odds ratio and confidence intervals.
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287esults
total of 68 stents were successfully placed in the coronary
rteries of 23 swine. Only in 1 case did an animal receive
nly 2 stents because of a too-small third coronary artery.
ll animals survived the follow-up period. At sacrifice, no
acroscopic evidence of stent thrombosis or myocardial
nfarction was seen.
uantitative angiography. Angiographic measurements are
ummarized in Table 2. Analysis of variance showed no
ifferences in vascular diameters before or after implantation
etween the groups. Linear regression analysis of the data
howed that acute gain was the only independent predictor
f late loss—not sirolimus dose, stent/artery ratio, or
oating.
ualitative histology. Histological analyses performed at 28
ays showed complete healing in HAp with the neointima
ontaining sparse erythrocytes and only few struts inflamed
Fig. 2). The HApR also showed complete healing with few
truts inflamed. However, the intimal thickening contained
ore extracellular matrix, and the endothelium was slightly
aised.
The HAp-25 and HApR-40 showed areas that were
elatively acellular with a granular appearance. These areas
lso contained variable amounts of fibrinoid (Fig. 3) and
losely packed erythrocytes. The luminal aspect of the
ntima showed a more normal neointima with partly raised
ndothelium and adherent leucocytes. Inflammation usually
oincided with a few eosinophils. Areas of abundant neo-
ntima contained abundant extracellular matrix and often
acuoles indicative of cell death.
Table 1. Polymer-Free Sirolimus HAp Coating Characteristics
Estimated
Thickness
Coating
Weight
Drug
Amount
HAp-25 1 m 77 g 25 g
HApR-40 1 m 160 g 40 g
HApR-100 1 m 318 g 100 g
HAp hydroxyapatite; HApR hydroxyapatite including drug release regulating lipid layer.
Table 2. Angiographic Analysis Showing the Angiographic Measurements P
Before After
HAp 2.73 0.19 2.79 0.28
HApR 2.81 0.24 2.80 0.26
HAp-25 2.69 0.27 2.80 0.25
HApR-40 2.75 0.17 2.85 0.19
HApR-100 2.74 0.22 2.78 0.24
Cypher 2.67 0.20 2.76 0.20
ANOVA p  0.80 p  0.96
*Regression analysis shows that acute gain is the only independent predictor of late loss (p 0.001),
only hydroxyapatite (HAp)-25 and hydroxyapatite including drug release regulating lipid layer (HApANOVA analysis of variance.The HApR-100 and Cypher showed a qualitative re-
ponse similar to HAp-25 and HApR-40 but with more
learly defined acellular intima-media border zones and
ore extensive fibrinoid (Fig. 3). In case of an extensive
nflammatory response, eosinophils were usually involved,
xtending into the luminal neointima (Cypher).
nﬂammation. Full inflammation (inflammatory cells sur-
ounding all struts, proximal, medial, and distal) was not
bserved in any HAp-containing stent. Partial inflamma-
ion (no more than a few struts associated with inflamma-
ion) occurred in 3 of 13 HAp-25 stents, 3 of 13 HApR-40
tents, 5 of 12 HApR-100 stents, and 2 of 12 Cypher stents.
n only 1 case (Fig. 2) were all mid and distal stent struts
urrounded by inflammatory cells (Cypher).
orphometric analysis. Morphometric analysis is summa-
ized in Table 3. Regression analysis showed that stent/
rtery ratio, release layer, and morphologic injury score were
ndependent predictors of intimal thickness at the site of the
tent struts (p  0.009, p  0.045, and p  0.001,
espectively). Dummy variable analysis showed that
Ap-25 resulted in significantly less thickness of neointima
han HAp and HApR (p  0.02 and p  0.01, respec-
ively). Assessment of neointimal area showed that only
orphologic injury score was an independent predictor—
ot stent/artery ratio. There was a trend for the release layer
p  0.056), HApR to show significantly more neointimal
rea than all DES.
Fibrinoid was observed in all groups. Regression analysis
howed that sirolimus dose was the only independent
redictor for the accumulation of fibrinoid (p  0.028).
lthough HAp showed less fibrinoid than all DES (p 
.012), the low-dose HAp-25 showed significantly less
brinoid than Cypher (p  0.005). Logistic regression
howed an odds ratio of 33 (confidence interval: 3 to 374)
or presence of fibrinoid with the highest sirolimus dose as
ompared with the reference group (no sirolimus).
Morphologic injury score, traditionally viewed as the
esult of mechanical injury, was not predicted by the
ngiographic parameters; only sirolimus dose and intimal
nflammation were independent predictors for injury.
ed During Stent Implantation at Follow-Up
Follow-Up Late Loss Stent/Artery Ratio
2.48 0.33 0.30 0.49 1.10 0.09
2.38 0.34 0.43 0.19 1.03 0.03
2.57 0.19 0.23 0.21* 1.09 0.08
2.50 0.25 0.34 0.20 1.09 0.04
2.45 0.39 0.33 0.33 1.10 0.03
2.43 0.27 0.32 0.24 1.08 0.05
p  0.77 p  0.79 p  0.27
limus dose, stent/artery ratio or coating. Regression analysis including dummyvariables shows that
r significantly (p 0.023).erform
not siro
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288iscussion
n important limitation of current DES are their associa-
ion with delayed healing and negative effects on
ndothelium-dependent vasomotor function distal to the
Figure 2. Histology of Sirolimus-Eluting Stents
The best and worst examples of the hydroxyapatite-coated stents loaded with
(hematoxylin-eosin stain).tent, which can even extend into the microvasculature h1–3,5). Because effects on vasomotor function are less or
bsent after bare metal stents, the drugs and the nondegrad-
ble polymer reservoirs are held responsible for these phe-
omena. Therefore, lower but still-effective drug doses in
ombination with nonpolymeric coatings might be less
(A, B) 40 g (C, D), and 100 g sirolimus (E, F) and Cypher (G, H)25 garmful for the recipient vasculature.
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289The main finding of the present study is that less
irolimus, released from nonpolymeric HAp, results in less
brinoid as a marker of vascular healing without increasing
he resulting neointima formation, as compared with
ypher.
irolimus, delayed healing, and preservation of lumen pat-
ncy. Sirolimus is known for inducing fibrinoid vascular
ecrosis (15,16), which is thought to be a toxic effect. We
ave observed an increase in fibrinoid in human atherec-
omy specimen from DES restenosis as late as 2 years
fter stenting (4). This indicates the persistence of an
ncomplete healing response. We postulate that a reduc-
ion in fibrinoid denotes less local toxicity, thereby
ndicating a faster healing response. The REDOX (Re-
uced Sirolimus Doses on the Bx Velocity Stent) trial
howed that lower doses of sirolimus effectively maintain
uminal patency for at least 12 months follow-up (17).
his highlights the feasibility of lowering sirolimus dose
ithout compromising efficacy.
Figure 3. Fibrinoid in High- and Medium-Dose Sirolimus Stents
Detail of stent struts surrounded by ﬁbrinoid (arrow). The amount of ﬁbrinoid
mus (B) (hematoxylin-eosin stain).
Table 3. Morphometric Analysis: NIT Was Measured on Resorcin-Fuchsin-Stai
HAp HApR HAp-25
NIT (m) 282 72 335 49 235 93
Area (mm2) 1.75 0.8 2.36 0.9 1.34 0.8
F (mm2) 0.007 0.008 0.01 0.01 0.05 0.05
Injury score 0.29 0.23 0.41 0.29 0.27 0.53
Regression analysis showed that: 1) for thickness of neointima (NIT): stent/artery ratio, release layer, a
(p 0.009, p 0.045, and p 0.001, respectively); HAp-25was significantly different fromHAp and
predictor of intimal area (p 0.001), with a trend for release layer (p 0.056); HApR was significa
respectively); 3) for fibrinoid (F),measured onhematoxylin-eosin stained sections: sirolimus dosewa
HApR-100, and Cypher (all p 0.012), andHAp-25was significantly different fromCypher (p 0.005
injury score (p 0.022 and p 0.001, respectively).Other abbreviations as in Table 2.iocompatibility of the HAp coating. Hydroxyapatite, a cal-
ium phosphate salt, is the main mineral component of
one. Because it is a naturally occurring material, it is
otentially an ideal biomaterial. Handling of HAp for the
urpose of coating coronary stents is difficult, however,
ecause the material can crack or flake off during stent
xpansion. Particle debris in general can induce inflamma-
ion and obscure the antiproliferative effects of drugs
18,19), whereas HAp particles of 1 to 2 m can activate
acrophages to secrete tumor necrosis factor- (20). The
urrent coating of HAp did not induce extensive fibrosis or an
nflammatory response, indicating its stability during implan-
ation. Because late HAp resorption by osteoclasts in bone is
ot proinflammatory, it is not expected to induce late inflam-
ation in the vasculature (21).
tudy limitations. To study vascular healing, it is desirable
o include several time points. Our study includes only 1, 28
ays, the time point of largest reduction in neointimal
hickness in animals using Cypher (22). This reduction is
pher (A) is considerably larger than in the intermediate dose at 40 g siroli-
ctions Taken From the Proximal, Medial, and Distal Region of the Stent
HApR-40 HApR-100 Cypher
1-Way ANOVA
p Values
257 110 239 79 273 90 NS
1.38 0.7 1.43 0.5 1.41 0.6 0.056
0.07 0.04 0.07 0.03 0.10 0.06 0.001
0.24 0.3 0.23 0.35 0.41 0.47 NS
phologic injury scorewere independent predictors of intimal thickness at the site of the stent struts
 0.02 and p 0.01, respectively); 2) for area: morphologic injury scorewas the only independent
erent from HAp-25, HApR-40, HApR-100, and Cypher (p 0.002, p 0.007, p 0.027, p 0.007,
ly independent predictor of F (p 0.028); HAp andHApRwere significantly different fromHApR-40,
) for injury score: sirolimus dose and intimal inflammationwere the only independent predictors forin Cyned Se
ndmor
HApR (p
ntly diff
s the on
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290ot always persistent in animal models studying DES
22,23). Such a late increase in intimal thickening might
ell be the result of a late increase in inflammation due to
he persistent presence of synthetic polymer coatings (24).
ecause the HAp-coated stents do not contain a polymeric
oating, we did not expect a late increase in neointima
hickness and inflammation. Because there is no doubt
bout long-term clinical benefit of the Cypher stent, later
ime points were not included.
Although our observation of fibrinoid stands on its own, we
o not know what the long-term fate of fibrinoid is. With the
ack of vasomotor studies to link fibrinoid presence to vascular
ysfunction, it remains to be determined whether low-dose
irolimus will indeed attenuate vascular dysfunction in response
o sirolimus in the distal vasculature.
onclusions
owering the dose of sirolimus eluting from a biocompat-
ble HAp-coated stent reduces signs of delayed vascular
ealing.
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